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Can [F-18] fluorodeoxyglucose positron emission tomography
replace sentinel lymph node biopsy for the detection of axillary
metastases in patients with early-stage breast cancer?*
Semih GÖRGÜLÜ1, Mehmet Fatih CAN1, Oğuz HANÇERLİOĞULLARI1, Nuri ARSLAN2,
Erkan ÖZTÜRK1, Emel ÖZTÜRK3, Müjdat BALKAN1, Turgut TUFAN1

Aim: To investigate the value of fluorodeoxyglucose positron emission tomography (FDG-PET) in detecting axillary
involvement, and to compare its accuracy with sentinel lymph node biopsy (SLNB) in patients with clinically early-stage
breast cancer.
Materials and methods: Twenty-eight female patients with histologically-confirmed T1-2 breast cancer who were
scheduled to have SLNB were included in the study. FDG-PET images were obtained 1-7 days prior to surgery with an
intravenous injection of 370 MBq of FDG, while plasma glucose levels were maintained below 120 mg/dL. All the images
were interpreted by 2 independent nuclear medicine specialists, who were blinded to the histological diagnoses. SLNB
was performed in standard fashion with peri-tumoral injection of isosulphan blue dye. In all cases, a level I-II axillary
dissection was performed following SLNB. Sentinel nodes were processed after formalin fixation; no frozen sections
were used.
Results: Thirteen (46%) patients were found to have axillary involvement. SLNB (an average of 2.3 LNs removed per
patient) demonstrated metastases in all 13 patients. The diagnostic accuracy of FDG-PET was as follows: true-positive
in 4 out of 13 patients (overall sensitivity = 31%), false-negative in 1 patient with metastasis (overall specificity = 94%),
positive predictive value = 80%, negative predictive value = 63%, and accuracy = 68%.
Conclusion: FDG-PET appears to be significantly less accurate than SLNB at detecting axillary metastases. In patients
with an axillary-positive PET scan, however, axillary lymph node dissection may be performed without prior SLNB.
Key words: Breast cancer, sentinel lymph node biopsy, positron emission tomography, axillary metastasis

[F-18] Deoksiglukoz pozitron emisyon tomografisi erken evre meme kanserli
hastaların aksiller metastazlarının tespitinde sentinel lenf nodu biyopsisinin yerini
alabilir mi?
Amaç: Florodeoksiglukoz positron emisyon tomografisinin (FDG-PET) erken evre meme kanserli hastalarda aksiller
tutulumu saptamadaki değerini araştırmak ve doğruluğunu sentinel lenf nodu biyopsisi (SLNB) ile karşılaştırmak.
Yöntem ve gereç: Histolojik olarak meme kanseri tanısı almış ve SLNB planlanan yirmi sekiz kadın hasta çalışmaya dahil
edildi. FDG-PET görüntüleri cerrahiden 1-7 gün önce, kan glukoz düzeyleri 120 mg/dL. nin altında tutularak 370 MBq
FDG’nin intravenöz enjeksiyonu ile elde edildi. Görüntüler birbirinden bağımsız ve histolojik tanılardan habersiz iki
nükleer tıp uzmanınca yorumlandı. SLNB standart şekilde izosülfan mavisinin peritümöral enjeksiyonu ile
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gerçekleştirildi. Tüm olgularda SLNB işlemini level I-II aksilla disksiyonu izledi. Sentinel nodlar formalin fiksasyonu
sonrası rutin takiple değerlendirildi.
Bulgular: 13 (% 46) hastada aksiller tutulum saptandı. SLNB (ortalama 2.3 lenf nodu/hasta) tüm hastalardaki metastazları
gösterdi. FDG-PET’in tanısal doğruluğu aşağıdaki şekildeydi: 13 hastanın 4’ünde gerçek-pozitif (duyarlılık =% 31),
hastaların 1’inde yalancı-negatif (özgüllük =% 94), pozitif prediktif değer =% 80, negatif prediktif değer =% 63, ve
doğruluk =% 68.
Sonuç: FDG-PET’in aksiller metastazları saptamadaki doğruluğu SLNB’den belirgin şekilde düşük bulunmuştur. Ancak
PET incelemesinin aksillayı pozitif gösterdiği olgularda SLNB uygulanmaksızın aksiller diseksiyona gidilebilir.
Anahtar sözcükler: Meme kanseri, sentinel lenf nodu biyopsisi, pozitron emisyon tomografisi, aksiller metastaz

Introduction
Breast cancer is the most common malignancy in
women (1), and the second most lethal cancer in the
US, despite the fact that 80% of all patients present
with stage I or II disease (2,3). The status of the
axillary lymph node is the single most powerful
independent predictor of prognosis, both for disease
recurrence and survival in breast cancer. No imaging
technique currently is available for the accurate
evaluation of axillary lymph node involvement.
Therefore, the best procedure for examining axillary
lymph nodes remains axillary lymph node dissection
(ALND) followed by pathological examination. As a
secondary function, axillary lymph node dissection
also helps to control local axillary disease. However,
only 30% of women with an invasive breast tumor of
diameter of ≤2 cm have axillary lymph node
metastases (4). Axillary lymph node dissection
confers no survival advantage when the lymph nodes
are not involved. Axillary dissection also can result in
significant short- and long-term sequelae and tends
to delay discharge from hospital (5). The morbidity of
ALND has led to the increased use of sentinel lymph
node biopsy (SLNB) as a less invasive alternative. This
technique has become the new standard of care in
patients with early-stage breast cancer in whom the
nodes clinically appear uninvolved (6). Nonetheless,
any technique that could identify positive lymph
nodes before surgery would have several advantages.
Imaging by positron emission tomography (PET)
using the radio-labeled glucose analogue 2-(fluorine18)-fluoro-2-deoxy-D-glucose (F-18 FDG) allows for
visualization of a wide variety of tumors, because of
the enhanced tracer uptake by malignant tissue, when
compared with surrounding benign tissues (7-9). The
available literature comparing the utility of PET
18

scanning versus SLNB while staging the axilla in early
stage breast cancer is limited. The general aim of this
study was to determine the appropriateness of PET as
an alternative to SLNB and ALND in early-stage
breast cancer patients.
Materials and methods
Twenty-eight women, mean age 54.4 ± 13.0 years,
with histologically proven breast cancer and
scheduled to have SLNB and ALND as part of their
surgical therapy, constituted the study population.
The study was conducted between May 2005 and
October 2006. The preoperative diagnosis was
confirmed by fine needle aspiration with cytology.
Males and patients with clinical stage III or IV disease,
uncontrolled diabetes mellitus, prior SLNB or ALND,
inflammatory breast cancer, or pregnancy were
excluded. The protocol of the study was approved by
the Institutional Ethics Committee, and written
informed consent was obtained from all patients.
PET imaging
PET studies, using an Ecat Exact scanner
(Siemens/CTI Knoxville, TN, USA), were performed
in patients 1-7 days before surgery. To standardize
blood glucose levels, patients were required to fast for
at least 4 h before scanning. Plasma glucose levels
were determined before FDG injection, and PET
imaging performed with plasma glucose levels below
120 mg/dL; 370 MBq (or 10 mCi) of FDG was
injected into an antecubital vein contralateral to the
tumor. Patients remained in the supine position with
their arms raised while in the imager. Positron
emission imaging commenced 45 min after the
administration of FDG. Before FDG injection, 2
contiguous bed position transmission scans (10 min
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each) were acquired with a rotating 68Ge rod source
for correction of attenuation of the mammary and
axillary regions. Two 20-min static emission studies
were acquired in the transmission positions, 45-60
min after FDG injection.
All images were interpreted separately by 2
experienced nuclear medicine physicians. PET
interpretations were blinded to the histopathological
findings. The images were read as positive if localized
FDG-uptake was increased relative to the
surrounding tissue. Quantitative measurement of the
single-pixel maximal standardized uptake value
(SUV), normalized to body weight, was performed for
any suspicious lesion. PET results were evaluated for
sensitivity, specificity, accuracy, and positive and
negative predictive values relative to the
histopathological diagnosis.
Surgery
Definitive surgery was performed within 7 days of
the PET scan. Since SLNB was not a routine operation
at the time of the study, complete ALND was
performed as part of SLNB validation and
implementation studies. SLNB was carried out and
followed by standard ALND (level I and II) and breast
conserving resection or modified radical mastectomy.
SLNB was performed using a blue dye technique, with
peri-tumoral injection (1 mL into each 4 side) of
isosulphan blue dye (Lymphazurin, 1%, Autosuture,
USA) using a 25-gauge needle. Approximately 10 min
after the dye injection, a small transverse incision was
made, slightly anterior to and just below the hairbearing area in the axilla. The dissection then was
extended down to the superficial fascia covering the
axillary fat pad. Meticulous blunt dissection was
performed to identify the dye-filled lymphatic tract
or blue stained SLN. When a dye-filled lymphatic
tract was detected first, it was followed proximally and
distally until the blue stained SN was identified. In
cases in which the SN was found first, the proximal
lymphatic channel was followed until it reached the
breast parenchyma. If a secondary lymph node was
stained blue, it also was dissected.
Histopathological examination
All SLNs were processed following formalin
fixation; no frozen sections were performed. SLNs
were cut into 2 mm thin slices and each slide was
embedded in separate paraffin blocks. For each block,

2 × 2 sections were cut at a distance of 100 μm. Half
of the sections were stained with hematoxylin-eosin,
and the rest underwent immunohistochemistry using
pancytokeratin staining. The specimen from ALND
was formalin fixed and paraffin embedded, and each
mold was sectioned twice for hematoxylin-eosin
staining.
In
invasive
carcinoma
cases,
immunohistochemistry using pancytokeratin staining
also was performed. Size, grade, margins, and
estrogen and progesterone status were determined.
Statistical analysis
Sensitivity, specificity, positive and negative
predictive values, and the accuracy of the PET
imaging technique were calculated using the
following formulas:
Sensitivity = TP/(TP + FN)
Specificity = TN/(TN + FP)
Positive predictive value = TP/(TP + FP)
Negative predictive value = TN/(TN + FN)
Accuracy = (TP + TN)/(TP + FP + FN + TN)
where TP is true positive, TN is true negative, FP is
false positive, and FN is false negative.
Results
The clinical characteristics of all 28 patients are
summarized in Table 1. Of these 28 patients, 13 (46%)
were noted to have at least one axillary metastasis. An
average of 2.3 lymph nodes were removed per patient
and labeled as SLN. The SLNs were positive for
metastasis in all 13 patients. The FDG-PET was truepositive in 4 of 13 patients with an axillary metastasis,
and the overall sensitivity of FDG-PET was 31%.
There was one false-positive result with FDG-PET,
and the overall specificity of PET scanning for the
detection of axillary lymph node metastases was 94%.
The positive and negative predictive value and
accuracy of FDG-PET for detection of axillary
metastases were 80%, 63%, and 68% respectively.
FDG-PET was false-negative for axillary lymph
node metastasis in 9 of 13 metastases. The smallest
metastatic lymph node that was visible using PET was
11 mm in diameter. The mean size of the lymph node
was 8.8 mm in false-negative cases, while it was 14.7
mm in patients with true positive PET scans.
19
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Table 1. Clinical characteristics of the 28 patients.
Characteristic
Age (Years)
≤ 50
≥ 51
Histologic type
Ductal
Lobular
Mixed
Tumor grade
I
II
III
Tumor size (cm)
≤ 0.5
0.5-1.0
1.1-2.0
2.0-5.0
> 5.0
ER-PR receptor status
Positive

Total No.

%

10
18

36
64

23
4
1

82
14
4

5
12
11

18
43
39

women with axillary lymph node involvement have
decreased (13). These factors have led many authors
to advocate more restricted use of ALND in patients
with early breast cancer, and the development of less
invasive and noninvasive means to stage axilla (14,15).
There is no imaging technique currently available
permitting the accurate determination of axillary
involvement. The development of sentinel lymph
node biopsy has enabled precise axillary staging
through a minimally invasive and less morbid
approach (16,17), but it still involves a surgical
procedure. A noninvasive imaging test that could
accurately stage the axilla in early stage breast cancer
clearly would be ideal (14).

Discussion

Sentinel lymph node mapping and dissection is a
highly sensitive and accurate technique for nodal
evaluation. It has been applied to the staging of
axillary lymph nodes in patients with breast cancer,
providing prognostic information, yet producing less
surgical morbidity than ALND. When performed by
an experienced surgeon and analyzed by an
experienced pathologist with serial sectioning and
immunohistochemical evaluation, SLNB is the most
accurate detection tool used in the staging of breast
cancer (18). In the present study, no false-negative
SLNB was observed. Nonetheless, SLNB has certain
limitations, in both locally advanced and clinically
early-stage breast cancer patients, including a falsenegative rate up to 17% (19). The common causes of
false-negative SLNB are blockage of lymphatic vessels
by tumor cells, improper injection techniques,
removal of only a single lymph node, and inadequate
surgical experience (18).

Axillary lymph node status is the single most
important prognostic factor and best predictor of
recurrence and survival in primary breast cancer
(4,10,11). Surgical removal and histopathological
examination of nodes still remains the standard way
to assess their involvement (12). However, axillary
dissection causes significant morbidity, including
wound infection, seroma formation, lymphedema,
restriction of arm and shoulder movement, and
numbness involving upper arm skin. These sequelae
are a major cause of emotional distress, functional
impairment, and additional cost of treatment. Over
recent decades, the mean size of presenting primary
tumors and, correspondingly, the percentage of

The clinical use of FDG-PET for staging is being
investigated for many human tumors, including breast
cancer (20-23). Since the first reported visualization of
lymph node metastases with FDG-PET in a
preclinical animal study in 1990 (24), a number of
studies have compared the accuracy of PET scanning
and ALND, with conflicting results. Some
investigators have concluded that FDG-PET is capable
of accurately assessing the nodal status of breast
cancer, and has relatively high sensitivity and
specificity (18). Greco et al. reported a sensitivity of
94% and specificity of 86% in 167 patients undergoing
ALND, but more than 40% of their patients had T2
tumors, and 43% of the patients had positive nodes,

Negative
Axillary metastasis
Positive
Micrometastasis
Macrometastasis
Negative

20

1
7
14
6
-

4
25
50
21
-

19

68

9

32

13
9
4
15

46
32
14
54
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suggesting that the subjects in this study generally had
more advanced disease (25). In a study by
Schirrmeister et al. sensitivity and specificity were
79% and 92%, respectively, with a false-negative rate
of 20%, when compared with ALND. However, only
89 of 117 patients were found to have breast cancer
(26). Based upon their series of 200 patients, Zornosa
et al. reported 84% sensitivity and 97% specificity for
FDG-PET at detecting axillary metastases (27). In
other investigations with smaller patient numbers,
researchers have reported similar findings, with the
sensitivity of preoperative FDG-PET ranging from
85% to 100% (9,21,25-31) (Table 2).
Despite the optimistic conclusions of initial
reports, recent studies have yielded conflicting results,
wherein the accuracy of FDG-PET has been
compared to the accuracy of SLN biopsy and ALND
(32-35). For instance, Barranger et al. reported a
sensitivity of 20% and specificity of 100% for the
detection of nodal metastases by means of FDG-PET
(32). In patients qualifying for sentinel node biopsy,
FDG-PET seems to perform less well. FDG-PET
missed 8 of 14 positive axillary metastases evaluated
by SLNB in a study by Guller et al., 8 of 10 patients in
a study by Fehr et al., and 13 of 36 in a study by Kumar

et al. (18,20,34). Similarly, Veronesi et al. compared
FDG-PET with SLNB for the identification of occult
metastases, and reported that the sensitivity of FDGPET for the detection of axillary metastases was 37%,
while the specificity and positive predictive values
were 96% and 88%, respectively (35).
In our study, the sensitivity and specificity of FDGPET for detecting axillary metastatic lymph nodes
were 27% and 100%, respectively. Despite the limited
sample size of our study, the results were enhanced by
blinded PET interpretation and the use of 2 PET
examiners. The present study demonstrates the
inability of PET to visualize axillary metastases. Our
results are similar to those published by Wahl et al.
and Veronesi et al. from larger series (33,35). The
limited spatial resolution of commercially available
PET devices and the presence of fewer metabolically
hyperactive cells in patients with micro-metastases
certainly appear to be the primary explanations for
the low sensitivity of PET at detecting microscopic
lymph node metastases.
Contrary to the limited sensitivity of PDG-PET at
detecting axillary metastases, we found PET scanning
to have high specificity and positive predictive value,
as reported in previous studies (20,27,32,35). There

Table 2. Sensitivity and specificity of FDG-PET scanning in detection of sentinel lymph
node and axillary metastasis in breast cancer patients.
Authors

Year

Cases (n)

Sensitivity (%)

Specificity (%)

Avril

1996

51

79

96

Utech

1996

124

100

75

Adler

1997

52

95

66

Crippa

1998

68

85

91

Smith

1998

50

90

91

Greco

2001

167

94

86

Schirrmeister

2001

117

79

92

Guller

2002

31

43

94

Zornosa

2003

200

84

97

Barranger

2003

32

20

100

Fehr

2004

24

20

93

Wahl

2004

360

61

80

Veronesi

2007

236

37

96

Present study

2007

28

31

94
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was only one false positive scan in our study, and the
specificity and positive predictive values of FDG-PET
were 94% and 80%, respectively, indicating that a
positive PET scan is a highly accurate diagnostic test,
when histopathological examination is used as the
gold standard. Therefore, a positive PET scan may be
useful for identifying patients for whom the axillary
approach could proceed directly to the ALND,
without prior SLNB.
Previous studies have found that FDG-PET is able
to provide additional information when assessing
patients with internal mammary or supraclavicular
metastatic nodes or distant metastasis (9,31).
However, it currently is premature to recommend a
preoperative PET scan for all patients as a routine
diagnostic tool (33).

In conclusion, SLNB remains the procedure of
choice for evaluating the histological status of axillary
lymph nodes in patients with early-stage breast
carcinoma. Given its current spatial resolution, PET
imaging appears insufficiently sensitive for localizing
microscopic sentinel node metastases. Based upon
our results and data from the literature, we conclude
that FDG-PET cannot replace SLNB in the detection
of axillary metastases. On the other hand, the high
specificity of FDG-PET imaging may be useful to
identify patients who should undergo ALND rather
than SLNB for axillary staging. Better imaging devices
with higher resolution than current PET scanners,
better tracers, and novel technical developments in
PET technology may improve the detection rate of
axillary metastases in the near future.
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